drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB06595 | DB11560 | 1,491 | 1,678 | [
"DDInter1214",
"DDInter1038"
] | Midostaurin | Lesinurad | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter assoc... | Moderate | 1 | [
[
[
1491,
24,
1678
]
],
[
[
1491,
63,
1374
],
[
1374,
24,
1678
]
],
[
[
1491,
25,
877
],
[
877,
63,
1678
]
],
[
[
1491,
24,
1040
],
[
1040... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lesinurad"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
Midostaurin may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may c... |
DB00902 | DB06702 | 104 | 573 | [
"DDInter1168",
"DDInter731"
] | Methdilazine | Fesoterodine | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
104,
24,
573
]
],
[
[
104,
24,
211
],
[
211,
1,
573
]
],
[
[
104,
63,
494
],
[
494,
1,
573
]
],
[
[
104,
63,
100
],
[
100,
24,
... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Fesoterodi... |
DB00552 | DB08895 | 1,238 | 976 | [
"DDInter1425",
"DDInter1825"
] | Pentostatin | Tofacitinib | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
1238,
25,
976
]
],
[
[
1238,
24,
200
],
[
200,
63,
976
]
],
[
[
1238,
24,
1430
],
[
1430,
24,
976
]
],
[
[
1238,
25,
1011
],
[
1011,
... | [
[
[
"Pentostatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"C... | Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Sipule... |
DB00334 | DB11986 | 867 | 484 | [
"DDInter1326",
"DDInter648"
] | Olanzapine | Entrectinib | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
867,
24,
484
]
],
[
[
867,
23,
112
],
[
112,
23,
484
]
],
[
[
867,
24,
222
],
[
222,
23,
484
]
],
[
[
867,
24,
774
],
[
774,
24,... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Olanzapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Olanzapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Si... |
DB00451 | DB01377 | 542 | 1,283 | [
"DDInter1064",
"DDInter1119"
] | Levothyroxine | Magnesium oxide | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Moderate | 1 | [
[
[
542,
24,
1283
]
],
[
[
542,
62,
461
],
[
461,
23,
1283
]
],
[
[
542,
63,
1252
],
[
1252,
23,
1283
]
],
[
[
542,
24,
1482
],
[
1482,
... | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Timolol"
],
... | Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Timolol and Timolol may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin ... |
DB00446 | DB08899 | 597 | 129 | [
"DDInter351",
"DDInter649"
] | Chloramphenicol | Enzalutamide | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
597,
24,
129
]
],
[
[
597,
6,
8374
],
[
8374,
45,
129
]
],
[
[
597,
21,
28703
],
[
28703,
60,
129
]
],
[
[
597,
23,
271
],
[
271,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Chloramphenicol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} ... | Chloramphenicol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Chloramphenicol (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Mira... |
DB00327 | DB00574 | 421 | 121 | [
"DDInter890",
"DDInter717"
] | Hydromorphone | Fenfluramine | Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 a... | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Moderate | 1 | [
[
[
421,
24,
121
]
],
[
[
421,
35,
173
],
[
173,
62,
121
]
],
[
[
421,
24,
1347
],
[
1347,
63,
121
]
],
[
[
421,
1,
828
],
[
828,
24... | [
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
]
],
[
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when... | Hydromorphone (Compound) resembles Naloxone (Compound) and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Naloxone and Naloxone may cause a minor interaction that can limit clinical effects when taken with Fenfluramine
Hydromorphone may cause a moderate interaction that co... |
DB00472 | DB00731 | 758 | 1,144 | [
"DDInter758",
"DDInter1269"
] | Fluoxetine | Nateglinide | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
758,
24,
1144
]
],
[
[
758,
6,
6943
],
[
6943,
45,
1144
]
],
[
[
758,
21,
28787
],
[
28787,
60,
1144
]
],
[
[
758,
25,
121
],
[
121,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Fluoxetine",
"{u} (Compound) binds {v} (Gene)",
"ORM1"
],
[
"ORM1",
"{u} (Gene) is bound by {v} (Compound)",
... | Fluoxetine (Compound) binds ORM1 (Gene) and ORM1 (Gene) is bound by Nateglinide (Compound)
Fluoxetine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Fluoxetine may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may ... |
DB00653 | DB11921 | 544 | 1,019 | [
"DDInter1120",
"DDInter492"
] | Magnesium sulfate | Deflazacort | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
544,
24,
1019
]
],
[
[
544,
63,
355
],
[
355,
24,
1019
]
],
[
[
544,
24,
286
],
[
286,
24,
1019
]
],
[
[
544,
24,
646
],
[
646,
... | [
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
... | Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesiu... |
DB00701 | DB12332 | 1,091 | 1,619 | [
"DDInter90",
"DDInter1626"
] | Amprenavir | Rucaparib | Amprenavir is a protease inhibitor used to treat HIV infection. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1091,
24,
1619
]
],
[
[
1091,
23,
222
],
[
222,
23,
1619
]
],
[
[
1091,
25,
112
],
[
112,
23,
1619
]
],
[
[
1091,
24,
309
],
[
309,
... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Amprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
... | Amprenavir may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Amprenavir may lead to a major life threatening interaction when taken with Metronidazole and Metronidazole may cau... |
DB00927 | DB01165 | 1,559 | 1,539 | [
"DDInter712",
"DDInter1325"
] | Famotidine | Ofloxacin | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Moderate | 1 | [
[
[
1559,
24,
1539
]
],
[
[
1559,
62,
1467
],
[
1467,
1,
1539
]
],
[
[
1559,
63,
1176
],
[
1176,
1,
1539
]
],
[
[
1559,
24,
945
],
[
945,
... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enoxacin"
],
[
"... | Famotidine may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Ofloxacin (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Ofloxacin (Compound)
Famo... |
DB00619 | DB04574 | 1,419 | 177 | [
"DDInter909",
"DDInter684"
] | Imatinib | Estrone sulfate (topical) | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Estrone 3-sulfate is a steroid sulfate that is the 3-sulfate of estrone. It has a role as a human metabolite and a mouse metabolite. It is a 17-oxo steroid and a steroid sulfate. It is functionally related to an estrone. It is a conjugate acid of an estrone 3-sulfate(1-). It derives from a hydride of an estrane. | Moderate | 1 | [
[
[
1419,
24,
177
]
],
[
[
1419,
63,
380
],
[
380,
1,
177
]
],
[
[
1419,
24,
35
],
[
35,
1,
177
]
],
[
[
1419,
6,
10715
],
[
10715,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estrone sulfate"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conjugated estrogens"
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Estrone sulfate
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens (Compound) resembles Estrone sulfate (Compound)
Imatinib may cause a moderate in... |
DB00176 | DB11837 | 529 | 1,297 | [
"DDInter770",
"DDInter1351"
] | Fluvoxamine | Osilodrostat | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
529,
24,
1297
]
],
[
[
529,
23,
1135
],
[
1135,
23,
1297
]
],
[
[
529,
23,
466
],
[
466,
62,
1297
]
],
[
[
529,
25,
222
],
[
222,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Fluvoxamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Daroluta... |
DB00252 | DB00290 | 362 | 329 | [
"DDInter1460",
"DDInter219"
] | Phenytoin | Bleomycin | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Moderate | 1 | [
[
[
362,
24,
329
]
],
[
[
362,
21,
28769
],
[
28769,
60,
329
]
],
[
[
362,
63,
58
],
[
58,
24,
329
]
],
[
[
362,
24,
372
],
[
372,
6... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bleomycin"
]
],
[
[
"Phenytoin",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side Effe... | Phenytoin (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Bleomycin (Compound)
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01234 | DB09045 | 1,220 | 52 | [
"DDInter513",
"DDInter607"
] | Dexamethasone | Dulaglutide | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
1220,
24,
52
]
],
[
[
1220,
40,
1103
],
[
1103,
23,
52
]
],
[
[
1220,
24,
170
],
[
170,
23,
52
]
],
[
[
1220,
63,
609
],
[
609,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a ... | Dexamethasone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that c... |
DB00586 | DB09268 | 1,512 | 1,662 | [
"DDInter537",
"DDInter1464"
] | Diclofenac | Picosulfuric acid | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1512,
24,
1662
]
],
[
[
1512,
23,
16
],
[
16,
23,
1662
]
],
[
[
1512,
63,
1252
],
[
1252,
23,
1662
]
],
[
[
1512,
24,
1619
],
[
1619,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Linaclotide"
],
... | Diclofenac may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digo... |
DB00374 | DB09237 | 1,061 | 1,586 | [
"DDInter1852",
"DDInter1045"
] | Treprostinil | Levamlodipine | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
1061,
24,
1586
]
],
[
[
1061,
24,
578
],
[
578,
23,
1586
]
],
[
[
1061,
63,
1648
],
[
1648,
24,
1586
]
],
[
[
1061,
24,
549
],
[
549,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Levamlodipine
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and ... |
DB08899 | DB15328 | 129 | 829 | [
"DDInter649",
"DDInter1896"
] | Enzalutamide | Ubrogepant | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor ... | Major | 2 | [
[
[
129,
25,
829
]
],
[
[
129,
25,
1476
],
[
1476,
24,
829
]
],
[
[
129,
24,
1468
],
[
1468,
24,
829
]
],
[
[
129,
64,
578
],
[
578,
... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ubrogepant"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{... | Enzalutamide may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may caus... |
DB00018 | DB09472 | 199 | 1,383 | [
"DDInter945",
"DDInter1693"
] | Interferon alfa-n3 | Sodium sulfate | Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD). | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
199,
24,
1383
]
],
[
[
199,
24,
1031
],
[
1031,
24,
1383
]
],
[
[
199,
25,
593
],
[
593,
24,
1383
]
],
[
[
199,
24,
1031
],
[
1031,
... | [
[
[
"Interferon alfa-n3",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Interferon alfa-n3",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophy... | Interferon alfa-n3 may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Interferon alfa-n3 may lead to a major life threatening interaction when taken with Bupropion an... |
DB01225 | DB06441 | 500 | 936 | [
"DDInter645",
"DDInter283"
] | Enoxaparin | Cangrelor | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Major | 2 | [
[
[
500,
25,
936
]
],
[
[
500,
23,
1631
],
[
1631,
62,
936
]
],
[
[
500,
64,
97
],
[
97,
24,
936
]
],
[
[
500,
63,
383
],
[
383,
24,... | [
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
],
[
[
"Enoxaparin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",
... | Enoxaparin may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Cangrelor
Enoxaparin may lead to a major life threatening interaction when taken with Oxaprozin and Oxaprozin may cause a moderate ... |
DB00470 | DB01320 | 530 | 651 | [
"DDInter601",
"DDInter783"
] | Dronabinol | Fosphenytoin | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
530,
24,
651
]
],
[
[
530,
23,
307
],
[
307,
1,
651
]
],
[
[
530,
63,
362
],
[
362,
1,
651
]
],
[
[
530,
6,
6017
],
[
6017,
45,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Dronabinol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
... | Dronabinol may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Fosphenytoin (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Dr... |
DB00364 | DB00612 | 417 | 1,121 | [
"DDInter1717",
"DDInter216"
] | Sucralfate | Bisoprolol | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | Minor | 0 | [
[
[
417,
23,
1121
]
],
[
[
417,
23,
819
],
[
819,
40,
1121
]
],
[
[
417,
62,
88
],
[
88,
40,
1121
]
],
[
[
417,
21,
28882
],
[
28882,
... | [
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bisoprolol"
]
],
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acebutolol"
],
[
... | Sucralfate may cause a minor interaction that can limit clinical effects when taken with Acebutolol and Acebutolol (Compound) resembles Bisoprolol (Compound)
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Metoprolol and Metoprolol (Compound) resembles Bisoprolol (Compound)
Sucr... |
DB06204 | DB11817 | 768 | 1,259 | [
"DDInter1746",
"DDInter165"
] | Tapentadol | Baricitinib | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Moderate | 1 | [
[
[
768,
24,
1259
]
],
[
[
768,
24,
407
],
[
407,
24,
1259
]
],
[
[
768,
64,
475
],
[
475,
24,
1259
]
],
[
[
768,
64,
1053
],
[
1053,
... | [
[
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
... | Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Tapentadol may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate in... |
DB06616 | DB11828 | 594 | 1,406 | [
"DDInter224",
"DDInter1281"
] | Bosutinib | Neratinib | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Moderate | 1 | [
[
[
594,
24,
1406
]
],
[
[
594,
25,
1510
],
[
1510,
24,
1406
]
],
[
[
594,
24,
1475
],
[
1475,
24,
1406
]
],
[
[
594,
63,
1117
],
[
1117,
... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunom... | Bosutinib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Sodium citrate and Sodium citrate... |
DB00342 | DB00529 | 1,181 | 789 | [
"DDInter1770",
"DDInter779"
] | Terfenadine | Foscarnet | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Moderate | 1 | [
[
[
1181,
24,
789
]
],
[
[
1181,
23,
112
],
[
112,
62,
789
]
],
[
[
1181,
24,
1494
],
[
1494,
24,
789
]
],
[
[
1181,
24,
770
],
[
770,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Foscarnet
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and P... |
DB00400 | DB09073 | 353 | 951 | [
"DDInter843",
"DDInter1379"
] | Griseofulvin | Palbociclib | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
353,
24,
951
]
],
[
[
353,
24,
907
],
[
907,
62,
951
]
],
[
[
353,
23,
271
],
[
271,
23,
951
]
],
[
[
353,
24,
479
],
[
479,
23,... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doravirine"
],
... | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirab... |
DB00682 | DB15233 | 126 | 1,650 | [
"DDInter1951",
"DDInter142"
] | Warfarin | Avapritinib | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
126,
25,
1650
]
],
[
[
126,
24,
1478
],
[
1478,
24,
1650
]
],
[
[
126,
63,
58
],
[
58,
24,
1650
]
],
[
[
126,
23,
918
],
[
918,
... | [
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept ma... |
DB00586 | DB01021 | 1,512 | 674 | [
"DDInter537",
"DDInter1861"
] | Diclofenac | Trichlormethiazide | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Moderate | 1 | [
[
[
1512,
24,
674
]
],
[
[
1512,
63,
1014
],
[
1014,
40,
674
]
],
[
[
1512,
24,
178
],
[
178,
1,
674
]
],
[
[
1512,
24,
359
],
[
359,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
]... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles Trichl... |
DB01234 | DB08882 | 1,220 | 1,281 | [
"DDInter513",
"DDInter1070"
] | Dexamethasone | Linagliptin | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
1220,
24,
1281
]
],
[
[
1220,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
1220,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
1220,
21,
30552
],
[
305... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Dexamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Dexamethasone (Compound) causes Diabetic (Side Effect) and... |
DB00261 | DB08899 | 702 | 129 | [
"DDInter93",
"DDInter649"
] | Anagrelide | Enzalutamide | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
702,
25,
129
]
],
[
[
702,
25,
918
],
[
918,
1,
129
]
],
[
[
702,
21,
28703
],
[
28703,
60,
129
]
],
[
[
702,
23,
1247
],
[
1247,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
... | Anagrelide may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Anagrelide (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Anagrelide may cause a minor interaction that can lim... |
DB06402 | DB11110 | 1,079 | 603 | [
"DDInter1756",
"DDInter1115"
] | Telavancin | Magnesium citrate | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
1079,
24,
603
]
],
[
[
1079,
64,
57
],
[
57,
24,
603
]
],
[
[
1079,
24,
1616
],
[
1616,
24,
603
]
],
[
[
1079,
63,
1151
],
[
1151,
... | [
[
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Telavancin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Telavancin may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and His... |
DB00280 | DB12500 | 494 | 283 | [
"DDInter575",
"DDInter714"
] | Disopyramide | Fedratinib | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
494,
24,
283
]
],
[
[
494,
25,
351
],
[
351,
23,
283
]
],
[
[
494,
24,
1419
],
[
1419,
24,
283
]
],
[
[
494,
40,
211
],
[
211,
2... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Riboci... | Disopyramide may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a ... |
DB00445 | DB12500 | 322 | 283 | [
"DDInter655",
"DDInter714"
] | Epirubicin | Fedratinib | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
322,
24,
283
]
],
[
[
322,
25,
351
],
[
351,
23,
283
]
],
[
[
322,
24,
1339
],
[
1339,
62,
283
]
],
[
[
322,
24,
479
],
[
479,
2... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib... | Epirubicin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat and Berotralstat may caus... |
DB00773 | DB01206 | 896 | 37 | [
"DDInter702",
"DDInter1086"
] | Etoposide | Lomustine | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | An alkylating agent of value against both hematologic malignancies and solid tumors. | Moderate | 1 | [
[
[
896,
24,
37
]
],
[
[
896,
5,
11613
],
[
11613,
44,
37
]
],
[
[
896,
6,
8374
],
[
8374,
45,
37
]
],
[
[
896,
21,
28722
],
[
28722,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Etoposide",
"{u} (Compound) treats {v} (Disease)",
"brain cancer"
],
[
"brain cancer",
"{u} (Disease) is treated b... | Etoposide (Compound) treats brain cancer (Disease) and brain cancer (Disease) is treated by Lomustine (Compound)
Etoposide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomustine (Compound)
Etoposide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lomustine (Compound)
Etoposi... |
DB08880 | DB09331 | 1,510 | 745 | [
"DDInter1771",
"DDInter478"
] | Teriflunomide | Daratumumab | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the trea... | Major | 2 | [
[
[
1510,
25,
745
]
],
[
[
1510,
64,
139
],
[
139,
24,
745
]
],
[
[
1510,
63,
597
],
[
597,
24,
745
]
],
[
[
1510,
25,
287
],
[
287,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daratumumab"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
... | Teriflunomide may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramph... |
DB00912 | DB06016 | 473 | 1,508 | [
"DDInter1581",
"DDInter300"
] | Repaglinide | Cariprazine | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Moderate | 1 | [
[
[
473,
24,
1508
]
],
[
[
473,
24,
1593
],
[
1593,
63,
1508
]
],
[
[
473,
63,
600
],
[
600,
24,
1508
]
],
[
[
473,
24,
1021
],
[
1021,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fl... |
DB00029 | DB04865 | 25 | 4 | [
"DDInter99",
"DDInter1335"
] | Anistreplase | Omacetaxine mepesuccinate | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Major | 2 | [
[
[
25,
25,
4
]
],
[
[
25,
24,
738
],
[
738,
63,
4
]
],
[
[
25,
25,
39
],
[
39,
63,
4
]
],
[
[
25,
25,
1213
],
[
1213,
24,
4
... | [
[
[
"Anistreplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[... | Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Anistreplase may lead to a major life threatening interaction when taken with Panobinostat and Pa... |
DB01229 | DB04865 | 973 | 4 | [
"DDInter1377",
"DDInter1335"
] | Paclitaxel | Omacetaxine mepesuccinate | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
973,
24,
4
]
],
[
[
973,
7,
13042
],
[
13042,
46,
4
]
],
[
[
973,
18,
10351
],
[
10351,
46,
4
]
],
[
[
973,
18,
10488
],
[
10488,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Paclitaxel",
"{u} (Compound) upregulates {v} (Gene)",
"HIST1H2BK"
],
[
"HIST1H2BK",
"{u} (Gene) i... | Paclitaxel (Compound) upregulates HIST1H2BK (Gene) and HIST1H2BK (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Paclitaxel (Compound) downregulates ATF6 (Gene) and ATF6 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Paclitaxel (Compound) downregulates B4GAT1 (Gene) and B4GAT1 (Gene) is dow... |
DB08826 | DB08870 | 1,292 | 850 | [
"DDInter489",
"DDInter228"
] | Deferiprone | Brentuximab vedotin | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Major | 2 | [
[
[
1292,
25,
850
]
],
[
[
1292,
64,
611
],
[
611,
24,
850
]
],
[
[
1292,
25,
1583
],
[
1583,
63,
850
]
],
[
[
1292,
63,
1512
],
[
1512,
... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacarbazine"
],
[
"Dacarbazine",... | Deferiprone may lead to a major life threatening interaction when taken with Dacarbazine and Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Deferiprone may lead to a major life threatening interaction when taken with Sarilumab and Sarilumab may cause a mo... |
DB00697 | DB11901 | 876 | 913 | [
"DDInter1821",
"DDInter107"
] | Tizanidine | Apalutamide | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
876,
24,
913
]
],
[
[
876,
23,
112
],
[
112,
23,
913
]
],
[
[
876,
63,
600
],
[
600,
24,
913
]
],
[
[
876,
24,
485
],
[
485,
24,... | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Tizanidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Tizanidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fl... |
DB00349 | DB01246 | 902 | 820 | [
"DDInter401",
"DDInter45"
] | Clobazam | Alimemazine | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike old... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
902,
24,
820
]
],
[
[
902,
24,
104
],
[
104,
40,
820
]
],
[
[
902,
40,
1335
],
[
1335,
24,
820
]
],
[
[
902,
24,
401
],
[
401,
2... | [
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Clobazam (Compound) resembles Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Alim... |
DB00060 | DB12001 | 912 | 564 | [
"DDInter947",
"DDInter7"
] | Interferon beta-1a | Abemaciclib | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Moderate | 1 | [
[
[
912,
24,
564
]
],
[
[
912,
24,
868
],
[
868,
24,
564
]
],
[
[
912,
24,
242
],
[
242,
63,
564
]
],
[
[
912,
25,
139
],
[
139,
24,... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafeni... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Re... |
DB01246 | DB09293 | 820 | 116 | [
"DDInter45",
"DDInter954"
] | Alimemazine | Iodide I-131 | A phenothiazine derivative that is used as an antipruritic. | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Moderate | 1 | [
[
[
820,
24,
116
]
],
[
[
820,
63,
701
],
[
701,
24,
116
]
],
[
[
820,
25,
1487
],
[
1487,
24,
116
]
],
[
[
820,
24,
516
],
[
516,
2... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
... | Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Alimemazine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxych... |
DB00363 | DB00816 | 695 | 1,674 | [
"DDInter419",
"DDInter1346"
] | Clozapine | Orciprenaline | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Major | 2 | [
[
[
695,
25,
1674
]
],
[
[
695,
24,
874
],
[
874,
24,
1674
]
],
[
[
695,
63,
1685
],
[
1685,
24,
1674
]
],
[
[
695,
24,
959
],
[
959,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Orciprenaline"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
"Epinephr... | Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and ... |
DB08868 | DB11601 | 1,011 | 1,270 | [
"DDInter737",
"DDInter1889"
] | Fingolimod | Tuberculin purified protein derivative | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
1011,
24,
1270
]
],
[
[
1011,
25,
350
],
[
350,
24,
1270
]
],
[
[
1011,
64,
550
],
[
550,
24,
1270
]
],
[
[
1011,
25,
119
],
[
119,
... | [
[
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
... | Fingolimod may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Fingolimod may lead to a major life threatening interaction when taken with Trastuzumab and Trast... |
DB00911 | DB04855 | 458 | 540 | [
"DDInter1811",
"DDInter602"
] | Tinidazole | Dronedarone | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Moderate | 1 | [
[
[
458,
24,
540
]
],
[
[
458,
24,
33
],
[
33,
40,
540
]
],
[
[
458,
6,
8374
],
[
8374,
45,
540
]
],
[
[
458,
21,
28883
],
[
28883,
... | [
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
],
[
... | Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone (Compound) resembles Dronedarone (Compound)
Tinidazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dronedarone (Compound)
Tinidazole (Compound) causes Skin disorder (Side Effect) and Ski... |
DB00685 | DB01030 | 1,299 | 869 | [
"DDInter1887",
"DDInter1835"
] | Trovafloxacin | Topotecan | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Minor | 0 | [
[
[
1299,
23,
869
]
],
[
[
1299,
23,
613
],
[
613,
24,
869
]
],
[
[
1299,
6,
3199
],
[
3199,
57,
869
]
],
[
[
1299,
21,
29276
],
[
29276,
... | [
[
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Topotecan"
]
],
[
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Irinotecan"
],
[
... | Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Trovafloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Topotecan (Compound)
Trovafloxa... |
DB00999 | DB01261 | 504 | 170 | [
"DDInter883",
"DDInter1679"
] | Hydrochlorothiazide | Sitagliptin | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
504,
24,
170
]
],
[
[
504,
21,
28850
],
[
28850,
60,
170
]
],
[
[
504,
24,
52
],
[
52,
62,
170
]
],
[
[
504,
24,
708
],
[
708,
6... | [
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Hydrochlorothiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Back pain"
],
[
"Back pain",
"{u} (S... | Hydrochlorothiazide (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Sitagliptin (Compound)
Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a minor interaction that can limit clinical effects when... |
DB01267 | DB09078 | 519 | 1,228 | [
"DDInter1381",
"DDInter1036"
] | Paliperidone | Lenvatinib | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
519,
24,
1228
]
],
[
[
519,
62,
112
],
[
112,
23,
1228
]
],
[
[
519,
63,
609
],
[
609,
24,
1228
]
],
[
[
519,
24,
1151
],
[
1151,
... | [
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Paliperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Paliperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin ... |
DB01224 | DB06616 | 623 | 594 | [
"DDInter1553",
"DDInter224"
] | Quetiapine | Bosutinib | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
623,
24,
594
]
],
[
[
623,
6,
8374
],
[
8374,
45,
594
]
],
[
[
623,
7,
4786
],
[
4786,
45,
594
]
],
[
[
623,
18,
5833
],
[
5833,
... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Quetiapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Quetiapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Quetiapine (Compound) upregulates EPHB2 (Gene) and EPHB2 (Gene) is bound by Bosutinib (Compound)
Quetiapine (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is upregulated by Bosutinib (Compound)
Quetiapine (Compound) cau... |
DB00637 | DB00889 | 1,557 | 1,133 | [
"DDInter128",
"DDInter840"
] | Astemizole | Granisetron | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Moderate | 1 | [
[
[
1557,
24,
1133
]
],
[
[
1557,
6,
8374
],
[
8374,
45,
1133
]
],
[
[
1557,
18,
10375
],
[
10375,
57,
1133
]
],
[
[
1557,
23,
112
],
[
11... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Astemizole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Astemizole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Granisetron (Compound)
Astemizole (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Granisetron (Compound)
Astemizole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metroni... |
DB00420 | DB14568 | 508 | 982 | [
"DDInter1532",
"DDInter1000"
] | Promazine | Ivosidenib | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
508,
25,
982
]
],
[
[
508,
23,
112
],
[
112,
23,
982
]
],
[
[
508,
24,
543
],
[
543,
24,
982
]
],
[
[
508,
25,
11
],
[
11,
25,
... | [
[
[
"Promazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Promazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazo... | Promazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Lopera... |
DB06228 | DB11652 | 792 | 1,155 | [
"DDInter1609",
"DDInter1891"
] | Rivaroxaban | Tucatinib | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
792,
24,
1155
]
],
[
[
792,
63,
222
],
[
222,
23,
1155
]
],
[
[
792,
63,
1424
],
[
1424,
24,
1155
]
],
[
[
792,
24,
466
],
[
466,
... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine ... |
DB09054 | DB12887 | 384 | 1,598 | [
"DDInter905",
"DDInter1750"
] | Idelalisib | Tazemetostat | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Major | 2 | [
[
[
384,
25,
1598
]
],
[
[
384,
63,
608
],
[
608,
23,
1598
]
],
[
[
384,
64,
594
],
[
594,
24,
1598
]
],
[
[
384,
25,
985
],
[
985,
... | [
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tazemetostat"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine... | Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Idelalisib may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a mo... |
DB00570 | DB08820 | 147 | 1,478 | [
"DDInter1936",
"DDInter997"
] | Vinblastine | Ivacaftor | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
147,
24,
1478
]
],
[
[
147,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
147,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
147,
23,
307
],
[
307,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Vinblastine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Vinblastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Vinblastine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafini... |
DB00262 | DB10583 | 552 | 949 | [
"DDInter302",
"DDInter415"
] | Carmustine | Clostridium tetani toxoid antigen (formaldehyde inactivated) | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Moderate | 1 | [
[
[
552,
24,
949
]
],
[
[
552,
24,
589
],
[
589,
24,
949
]
],
[
[
552,
25,
1377
],
[
1377,
24,
949
]
],
[
[
552,
63,
58
],
[
58,
24,... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when t... | Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Carmustine may lead to a major life threatening interaction when... |
DB01064 | DB01234 | 1,148 | 1,220 | [
"DDInter987",
"DDInter513"
] | Isoprenaline | Dexamethasone | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Minor | 0 | [
[
[
1148,
23,
1220
]
],
[
[
1148,
62,
870
],
[
870,
1,
1220
]
],
[
[
1148,
62,
175
],
[
175,
40,
1220
]
],
[
[
1148,
23,
617
],
[
617,
... | [
[
[
"Isoprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
],
[
[
"Isoprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludrocortisone"
],
... | Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Triamcinolone and Triamcinolone (Compound) resembles Dex... |
DB00443 | DB01115 | 251 | 336 | [
"DDInter195",
"DDInter1291"
] | Betamethasone | Nifedipine | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Moderate | 1 | [
[
[
251,
24,
336
]
],
[
[
251,
63,
1428
],
[
1428,
1,
336
]
],
[
[
251,
24,
1081
],
[
1081,
40,
336
]
],
[
[
251,
24,
409
],
[
409,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Nifedipine (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine (Compound) resembles Nifedipine (Co... |
DB00700 | DB01142 | 312 | 1,264 | [
"DDInter656",
"DDInter593"
] | Eplerenone | Doxepin | Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone c... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
312,
24,
1264
]
],
[
[
312,
24,
401
],
[
401,
24,
1264
]
],
[
[
312,
6,
8374
],
[
8374,
45,
1264
]
],
[
[
312,
21,
28898
],
[
28898,
... | [
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Eplerenone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxepin (Compound)
Eplerenone (Compound... |
DB00819 | DB08907 | 471 | 1,344 | [
"DDInter15",
"DDInter280"
] | Acetazolamide | Canagliflozin | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
471,
24,
1344
]
],
[
[
471,
24,
549
],
[
549,
1,
1344
]
],
[
[
471,
6,
8374
],
[
8374,
45,
1344
]
],
[
[
471,
21,
29152
],
[
29152,
... | [
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
... | Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Acetazolamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Canagliflozin (Compound)
Acetazolamide (Compound) causes Thirst (Side Eff... |
DB03904 | DB14575 | 1,574 | 733 | [
"DDInter1903",
"DDInter674"
] | Urea | Eslicarbazepine | A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
1574,
24,
733
]
],
[
[
1574,
63,
222
],
[
222,
24,
733
]
],
[
[
1574,
63,
222
],
[
222,
25,
1264
],
[
1264,
24,
733
]
],
[
[
1574,
... | [
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"S... | Urea may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Urea may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramin... |
DB00019 | DB01030 | 1,257 | 869 | [
"DDInter1405",
"DDInter1835"
] | Pegfilgrastim | Topotecan | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Moderate | 1 | [
[
[
1257,
24,
869
]
],
[
[
1257,
24,
613
],
[
613,
24,
869
]
],
[
[
1257,
24,
310
],
[
310,
63,
869
]
],
[
[
1257,
25,
1064
],
[
1064,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
],
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and ... |
DB00741 | DB01116 | 167 | 601 | [
"DDInter885",
"DDInter1872"
] | Hydrocortisone | Trimethaphan | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery. | Moderate | 1 | [
[
[
167,
24,
601
]
],
[
[
167,
24,
998
],
[
998,
1,
601
]
],
[
[
167,
25,
593
],
[
593,
63,
601
]
],
[
[
167,
1,
891
],
[
891,
24,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethaphan"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Trimethaphan (Compound)
Hydrocortisone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that coul... |
DB01392 | DB06704 | 425 | 247 | [
"DDInter1954",
"DDInter952"
] | Yohimbine | Iobenguane (I-131) | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Major | 2 | [
[
[
425,
25,
247
]
],
[
[
425,
40,
1340
],
[
1340,
37,
247
]
],
[
[
425,
1,
1245
],
[
1245,
37,
247
]
],
[
[
425,
40,
1340
],
[
1340,
... | [
[
[
"Yohimbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Yohimbine",
"{u} (Compound) resembles {v} (Compound)",
"Deserpidine"
],
[
"Deserpidine",
"{u} may cause a moderate interaction t... | Yohimbine may lead to a major life threatening interaction when taken with Iobenguane
Yohimbine (Compound) resembles Deserpidine (Compound) and Deserpidine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Deserpidine may lead to a major life threatening interaction when tak... |
DB00465 | DB09268 | 886 | 1,662 | [
"DDInter1010",
"DDInter1464"
] | Ketorolac | Picosulfuric acid | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
886,
24,
1662
]
],
[
[
886,
23,
16
],
[
16,
23,
1662
]
],
[
[
886,
25,
1618
],
[
1618,
24,
1662
]
],
[
[
886,
24,
91
],
[
91,
24... | [
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Ketorolac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Linaclotide"
],
... | Ketorolac may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Ketorolac may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may... |
DB01185 | DB04865 | 155 | 4 | [
"DDInter759",
"DDInter1335"
] | Fluoxymesterone | Omacetaxine mepesuccinate | An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
155,
24,
4
]
],
[
[
155,
6,
1899
],
[
1899,
46,
4
]
],
[
[
155,
24,
1296
],
[
1296,
63,
4
]
],
[
[
155,
25,
350
],
[
350,
63,
... | [
[
[
"Fluoxymesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Fluoxymesterone",
"{u} (Compound) binds {v} (Gene)",
"NR3C1"
],
[
"NR3C1",
"{u} (Gene) is up... | Fluoxymesterone (Compound) binds NR3C1 (Gene) and NR3C1 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Fluoxymesterone may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when... |
DB06791 | DB11978 | 1,446 | 124 | [
"DDInter1021",
"DDInter822"
] | Lanreotide | Glasdegib | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1446,
24,
124
]
],
[
[
1446,
23,
466
],
[
466,
62,
124
]
],
[
[
1446,
24,
159
],
[
159,
63,
124
]
],
[
[
1446,
24,
1586
],
[
1586,
... | [
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Lanreotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
... | Lanreotide may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Laro... |
DB00209 | DB00373 | 352 | 461 | [
"DDInter1886",
"DDInter1809"
] | Trospium | Timolol | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Moderate | 1 | [
[
[
352,
24,
461
]
],
[
[
352,
24,
729
],
[
729,
40,
461
]
],
[
[
352,
6,
12523
],
[
12523,
45,
461
]
],
[
[
352,
21,
28769
],
[
28769,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
],
[
"Pe... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Timolol (Compound)
Trospium (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Timolol (Compound)
Trospium (Compound) causes Feeling abnormal (Side Effect) and Feeling abnorm... |
DB06788 | DB11113 | 1,616 | 657 | [
"DDInter864",
"DDInter307"
] | Histrelin | Castor oil | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
1616,
24,
657
]
],
[
[
1616,
63,
1079
],
[
1079,
24,
657
]
],
[
[
1616,
24,
927
],
[
927,
63,
657
]
],
[
[
1616,
64,
540
],
[
540,
... | [
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
... | Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encoraf... |
DB00701 | DB09098 | 1,091 | 98 | [
"DDInter90",
"DDInter1700"
] | Amprenavir | Somatrem | Amprenavir is a protease inhibitor used to treat HIV infection. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1091,
24,
98
]
],
[
[
1091,
64,
608
],
[
608,
23,
98
]
],
[
[
1091,
63,
168
],
[
168,
23,
98
]
],
[
[
1091,
25,
159
],
[
159,
63... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
... | Amprenavir may lead to a major life threatening interaction when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a mino... |
DB00497 | DB11817 | 828 | 1,259 | [
"DDInter1366",
"DDInter165"
] | Oxycodone | Baricitinib | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Moderate | 1 | [
[
[
828,
24,
1259
]
],
[
[
828,
40,
421
],
[
421,
24,
1259
]
],
[
[
828,
24,
927
],
[
927,
24,
1259
]
],
[
[
828,
64,
475
],
[
475,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Oxycodone",
"{u} (Compound) resembles {v} (Compound)",
"Hydromorphone"
],
[
"Hydromorphone",
"{u} may cause a mo... | Oxycodone (Compound) resembles Hydromorphone (Compound) and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction tha... |
DB00352 | DB14783 | 482 | 287 | [
"DDInter1814",
"DDInter574"
] | Tioguanine | Diroximel fumarate | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
482,
24,
287
]
],
[
[
482,
63,
1101
],
[
1101,
24,
287
]
],
[
[
482,
24,
384
],
[
384,
24,
287
]
],
[
[
482,
25,
770
],
[
770,
2... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib an... |
DB00398 | DB15093 | 79 | 1,654 | [
"DDInter1702",
"DDInter1698"
] | Sorafenib | Somapacitan | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
79,
24,
1654
]
],
[
[
79,
23,
1135
],
[
1135,
24,
1654
]
],
[
[
79,
25,
351
],
[
351,
24,
1654
]
],
[
[
79,
24,
310
],
[
310,
24... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Sorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Sorafenib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Sorafenib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a mod... |
DB08885 | DB10989 | 363 | 496 | [
"DDInter33",
"DDInter858"
] | Aflibercept | Hepatitis A Vaccine | Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Dalt... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
363,
24,
496
]
],
[
[
363,
63,
4
],
[
4,
24,
496
]
],
[
[
363,
24,
738
],
[
738,
63,
496
]
],
[
[
363,
25,
976
],
[
976,
24,
... | [
[
[
"Aflibercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Aflibercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepe... | Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Aflibercept may cause a moderate interaction that could exacerbate disea... |
DB00078 | DB10897 | 1,172 | 539 | [
"DDInter898",
"DDInter291"
] | Ibritumomab tiuxetan | Capsicum | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Capsicum (Chili pepper) allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
1172,
23,
539
]
],
[
[
1172,
25,
885
],
[
885,
23,
539
]
],
[
[
1172,
64,
582
],
[
582,
23,
539
]
],
[
[
1172,
24,
578
],
[
578,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
],
[... | Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Reteplase and Reteplase may cau... |
DB00060 | DB00339 | 912 | 1,182 | [
"DDInter947",
"DDInter1547"
] | Interferon beta-1a | Pyrazinamide | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | A pyrazine that is used therapeutically as an antitubercular agent. | Moderate | 1 | [
[
[
912,
24,
1182
]
],
[
[
912,
24,
384
],
[
384,
63,
1182
]
],
[
[
912,
63,
305
],
[
305,
24,
1182
]
],
[
[
912,
25,
1510
],
[
1510,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyrazinamide"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisi... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Pyrazinamide
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Asp... |
DB00396 | DB06203 | 989 | 1,002 | [
"DDInter1529",
"DDInter51"
] | Progesterone | Alogliptin | Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. Progesterone is used in var... | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
989,
24,
1002
]
],
[
[
989,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
989,
6,
12523
],
[
12523,
45,
1002
]
],
[
[
989,
21,
29321
],
[
2932... | [
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
... | Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Progesterone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Alogliptin (Compound)
Progesterone (Compound) causes Pancreatitis acute (Side Effe... |
DB01229 | DB04908 | 973 | 1,671 | [
"DDInter1377",
"DDInter741"
] | Paclitaxel | Flibanserin | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Moderate | 1 | [
[
[
973,
24,
1671
]
],
[
[
973,
63,
168
],
[
168,
23,
1671
]
],
[
[
973,
24,
741
],
[
741,
63,
1671
]
],
[
[
973,
63,
752
],
[
752,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Flibanserin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapit... |
DB00275 | DB00741 | 217 | 167 | [
"DDInter1330",
"DDInter885"
] | Olmesartan | Hydrocortisone | Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, w... | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
217,
24,
167
]
],
[
[
217,
24,
1220
],
[
1220,
40,
167
]
],
[
[
217,
24,
870
],
[
870,
1,
167
]
],
[
[
217,
21,
28642
],
[
28642,
... | [
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Hy... |
DB00393 | DB14568 | 854 | 982 | [
"DDInter1295",
"DDInter1000"
] | Nimodipine | Ivosidenib | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
854,
24,
982
]
],
[
[
854,
63,
1101
],
[
1101,
23,
982
]
],
[
[
854,
1,
1081
],
[
1081,
24,
982
]
],
[
[
854,
24,
770
],
[
770,
... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Nimodipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could... |
DB00059 | DB15822 | 1,560 | 69 | [
"DDInter1404",
"DDInter1504"
] | Pegaspargase | Pralsetinib | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small... | Moderate | 1 | [
[
[
1560,
24,
69
]
],
[
[
1560,
63,
1648
],
[
1648,
24,
69
]
],
[
[
1560,
24,
322
],
[
322,
24,
69
]
],
[
[
1560,
24,
609
],
[
609,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pralsetinib"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and... |
DB00313 | DB01097 | 556 | 1,377 | [
"DDInter1913",
"DDInter1033"
] | Valproic acid | Leflunomide | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investig... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
556,
25,
1377
]
],
[
[
556,
6,
6017
],
[
6017,
45,
1377
]
],
[
[
556,
21,
29062
],
[
29062,
60,
1377
]
],
[
[
556,
24,
126
],
[
126,
... | [
[
[
"Valproic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Valproic acid",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"... | Valproic acid (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound)
Valproic acid (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Leflunomide (Compound)
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Warf... |
DB00950 | DB15982 | 1,413 | 1,339 | [
"DDInter732",
"DDInter193"
] | Fexofenadine | Berotralstat | Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamin... | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat ... | Moderate | 1 | [
[
[
1413,
24,
1339
]
],
[
[
1413,
24,
1468
],
[
1468,
24,
1339
]
],
[
[
1413,
24,
868
],
[
868,
25,
1339
]
],
[
[
1413,
23,
609
],
[
609,
... | [
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
]
],
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
... | Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and V... |
DB11057 | DB11915 | 720 | 1,293 | [
"DDInter1223",
"DDInter1909"
] | Mineral oil | Valbenazine | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
720,
24,
1293
]
],
[
[
720,
63,
521
],
[
521,
24,
1293
]
],
[
[
720,
24,
927
],
[
927,
24,
1293
]
],
[
[
720,
24,
484
],
[
484,
... | [
[
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Enco... |
DB08870 | DB09121 | 850 | 1,328 | [
"DDInter228",
"DDInter140"
] | Brentuximab vedotin | Aurothioglucose | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased si... | Moderate | 1 | [
[
[
850,
24,
1328
]
],
[
[
850,
63,
367
],
[
367,
24,
1328
]
],
[
[
850,
64,
581
],
[
581,
24,
1328
]
],
[
[
850,
25,
375
],
[
375,
... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Inte... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Brentuximab vedotin may lead to a major life threatening interaction when take... |
DB01254 | DB04946 | 1,213 | 924 | [
"DDInter484",
"DDInter907"
] | Dasatinib | Iloperidone | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Major | 2 | [
[
[
1213,
25,
924
]
],
[
[
1213,
63,
883
],
[
883,
1,
924
]
],
[
[
1213,
64,
1425
],
[
1425,
25,
924
]
],
[
[
1213,
24,
519
],
[
519,
... | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Iloperidone (Compound)
Dasatinib may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken wit... |
DB00191 | DB09100 | 73 | 320 | [
"DDInter1447",
"DDInter1799"
] | Phentermine | Thyroid, porcine | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyro... | Moderate | 1 | [
[
[
73,
24,
320
]
],
[
[
73,
24,
127
],
[
127,
24,
320
]
],
[
[
73,
24,
1296
],
[
1296,
63,
320
]
],
[
[
73,
35,
22
],
[
22,
24,
... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec ... |
DB00491 | DB01069 | 127 | 401 | [
"DDInter1217",
"DDInter1533"
] | Miglitol | Promethazine | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
127,
24,
401
]
],
[
[
127,
24,
146
],
[
146,
24,
401
]
],
[
[
127,
24,
820
],
[
820,
63,
401
]
],
[
[
127,
21,
28787
],
[
28787,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
[
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Ali... |
DB00683 | DB12130 | 1,382 | 1,017 | [
"DDInter1212",
"DDInter1094"
] | Midazolam | Lorlatinib | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1382,
24,
1017
]
],
[
[
1382,
63,
608
],
[
608,
23,
1017
]
],
[
[
1382,
1,
686
],
[
686,
24,
1017
]
],
[
[
1382,
24,
629
],
[
629,
... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Midazolam (Compound) resembles Oxazepam (Compound) and Oxazepam may cause a moderate interaction that could exacerbat... |
DB00630 | DB00712 | 1,485 | 1,274 | [
"DDInter42",
"DDInter763"
] | Alendronic acid | Flurbiprofen | Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Moderate | 1 | [
[
[
1485,
24,
1274
]
],
[
[
1485,
7,
19948
],
[
19948,
46,
1274
]
],
[
[
1485,
18,
7623
],
[
7623,
57,
1274
]
],
[
[
1485,
21,
28769
],
[
... | [
[
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Alendronic acid",
"{u} (Compound) upregulates {v} (Gene)",
"CNPY3"
],
[
"CNPY3",
"{u} (Gene) is upregulat... | Alendronic acid (Compound) upregulates CNPY3 (Gene) and CNPY3 (Gene) is upregulated by Flurbiprofen (Compound)
Alendronic acid (Compound) downregulates RRP12 (Gene) and RRP12 (Gene) is downregulated by Flurbiprofen (Compound)
Alendronic acid (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Ef... |
DB00563 | DB01324 | 663 | 178 | [
"DDInter1174",
"DDInter1490"
] | Methotrexate | Polythiazide | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
663,
24,
178
]
],
[
[
663,
24,
674
],
[
674,
40,
178
]
],
[
[
663,
63,
1014
],
[
1014,
40,
178
]
],
[
[
663,
21,
28852
],
[
28852,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resemb... |
DB09498 | DB11703 | 810 | 405 | [
"DDInter1715",
"DDInter9"
] | Strontium chloride Sr-89 | Acalabrutinib | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
810,
24,
405
]
],
[
[
810,
63,
139
],
[
139,
24,
405
]
],
[
[
810,
24,
1619
],
[
1619,
63,
405
]
],
[
[
810,
63,
384
],
[
384,
2... | [
[
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when t... |
DB01138 | DB05676 | 804 | 1,513 | [
"DDInter1726",
"DDInter111"
] | Sulfinpyrazone | Apremilast | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July... | Moderate | 1 | [
[
[
804,
24,
1513
]
],
[
[
804,
25,
1421
],
[
1421,
63,
1513
]
],
[
[
804,
62,
1101
],
[
1101,
24,
1513
]
],
[
[
804,
24,
971
],
[
971,
... | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apremilast"
]
],
[
[
"Sulfinpyrazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Be... | Sulfinpyrazone may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Sulfinpyrazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may ... |
DB00407 | DB04865 | 202 | 4 | [
"DDInter115",
"DDInter1335"
] | Ardeparin | Omacetaxine mepesuccinate | Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Major | 2 | [
[
[
202,
25,
4
]
],
[
[
202,
63,
305
],
[
305,
24,
4
]
],
[
[
202,
24,
738
],
[
738,
63,
4
]
],
[
[
202,
25,
39
],
[
39,
63,
4... | [
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Ardeparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli... | Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Ardeparin may cause a moderate interaction that could exacer... |
DB00372 | DB00690 | 999 | 1,216 | [
"DDInter1793",
"DDInter762"
] | Thiethylperazine | Flurazepam | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | A benzodiazepine derivative used mainly as a hypnotic. | Moderate | 1 | [
[
[
999,
24,
1216
]
],
[
[
999,
24,
1382
],
[
1382,
1,
1216
]
],
[
[
999,
63,
902
],
[
902,
40,
1216
]
],
[
[
999,
63,
1174
],
[
1174,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Midazolam (Compound) resembles Flurazepam (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Flurazepam (Comp... |
DB00539 | DB01155 | 11 | 872 | [
"DDInter1837",
"DDInter813"
] | Toremifene | Gemifloxacin | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Major | 2 | [
[
[
11,
25,
872
]
],
[
[
11,
25,
739
],
[
739,
1,
872
]
],
[
[
11,
25,
945
],
[
945,
40,
872
]
],
[
[
11,
64,
1176
],
[
1176,
1,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
... | Toremifene may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gemifloxacin (Compound)
Toremifene may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gemifloxacin (Compound)
Toremifene may lea... |
DB00860 | DB06448 | 891 | 171 | [
"DDInter1513",
"DDInter1087"
] | Prednisolone | Lonafarnib | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Moderate | 1 | [
[
[
891,
24,
171
]
],
[
[
891,
1,
1351
],
[
1351,
24,
171
]
],
[
[
891,
24,
473
],
[
473,
24,
171
]
],
[
[
891,
63,
1101
],
[
1101,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Flunisolide"
],
[
"Flunisolide",
"{u} may cause a m... | Prednisolone (Compound) resembles Flunisolide (Compound) and Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction th... |
DB00593 | DB00902 | 1,464 | 104 | [
"DDInter695",
"DDInter1168"
] | Ethosuximide | Methdilazine | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
1464,
24,
104
]
],
[
[
1464,
63,
13
],
[
13,
24,
104
]
],
[
[
1464,
24,
820
],
[
820,
1,
104
]
],
[
[
1464,
24,
830
],
[
830,
40... | [
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]... | Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Alimema... |
DB00065 | DB08827 | 581 | 990 | [
"DDInter923",
"DDInter1085"
] | Infliximab | Lomitapide | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
581,
25,
990
]
],
[
[
581,
24,
1409
],
[
1409,
24,
990
]
],
[
[
581,
25,
973
],
[
973,
24,
990
]
],
[
[
581,
25,
1362
],
[
1362,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
],
[
"Apixaban",
... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Infliximab may lead to a major life threatening interaction when taken with Paclitaxel and Paclitaxel may cause a mo... |
DB01067 | DB01211 | 959 | 609 | [
"DDInter826",
"DDInter393"
] | Glipizide | Clarithromycin | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
959,
24,
609
]
],
[
[
959,
6,
8374
],
[
8374,
45,
609
]
],
[
[
959,
18,
4360
],
[
4360,
57,
609
]
],
[
[
959,
21,
28662
],
[
28662,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Glipizide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clarithromycin (Compound)
Glipizide (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Clarithromycin (Compound)
Glipizide (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Clarithromycin (Compound)... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.